전체 8345
-
- Autophagy Failure in Alzheimers Disease - A Therapeutic Target?
-
- - Ralph A. Nixon, MD, PhD, Nathan Kline Institute (2011/10/27)
- - Category : Neuroscience
- Neuroscience Seminar Series
Dr. Nixon？？？s research on Alzheimer？？？s disease and related neurodegenerative disorders began very early when he was a graduate student in Cell and Developmental Biology at Harvard and through periods of further training in Medicine and Psychiatry. As an independent investigator since the 1970s, his research has continuously focused on proteases and their regulation in health and disease. His research on calpains and on the lysosomal system has contributed significantly to our understanding of several fundamental and clinically important problems in aging and neurodegeneration. He has published over 250 manuscripts in peer-reviewed journals. He has successfully coordinated large teams of scientists as head of the largest research program McLean Hospital in the 1990？？？s; a larger Dementia Research Center at the Nathan Kline Institute in the past decade; and recently the NYU Center of Excellence on Brain Aging, a consolidated program linking all NKI and NYU dementia research which has as its principal mission facilitating the rapid translation of laboratory findings into clinically effective treatments and diagnostic modalities. These missions and objectives coincide with his long term goals to apply a novel mechanistic framework for understanding pathogenic actions of multiple genetic and environmental factors in AD to the development of effective therapeutic and prevention strategies. Dr. Nixon？？？s leadership responsibilities are now all consolidated within the area of AD research and treatment.
For more information, visit: http://neuroseries.info.nih.gov
Autophagy Failure in Alzheimers Disease - A Therapeutic Target?
-
- Careers in Psychology
-
- - Kim Nickerson, Ph.D., University of Maryland Cherly Boyce Ph.D, NIDA; Audrey Thurm, Ph.D, NIMH (2011/10/26)
- - Category : Career Development/OITE
- This workshop will provide you details about submitting your application for a doctoral program in psychology and how to obtain funding. Additionally, we will discuss research opportunities in the field.
For more information, visit: https://www.training.nih.gov/events/view/_2/690
Careers in Psychology
-
- Recombinant DNA Advisory Committee - September 2011 (Day 2)
-
- - NIH (2011/10/22)
- - Category : Recombinant DNA Advisory Committee
- National Institute of Health (NIH) Recombinant DNA Advisory Committee (RAC) 127th Meeting, Rockville Hilton & Executive Meeting Center
Recombinant DNA Advisory Committee - September 2011 (Day 2)
-
- Thalamus and Cortical Functioning
-
- - Murray Sherman, Ph.D., The University of Chicago (2011/10/22)
- - Category : Neuroscience
- Neuroscience Seminar Series
Murray Sherman？？？s research is directed at issues of thalamic functional organization, cortical functional organization and thalamocortical relationships. His laboratory uses a broad interdisciplinary approach, attempting to answer the same or closely related questions with several different techniques. These involve neuroanatomical, neurophysiological, and behavioral methods. More specifically, light and electron microscopic techniques are used to explore various circuits; in vitro recordings from brain slices are used to study cell and synaptic properties; and recording from single thalamic neurons in awake, behaving animals are used to determine the relationship between behavioral state and thalamic functioning.
For more information, visit: http://neuroseries.info.nih.gov
Thalamus and Cortical Functioning
-
- TRACO: Small molecules: Radiation oncology
-
- - Chris Austin: Kevin Camphausen (2011/10/22)
- - Category : TRACO
- The Translational Research in Clinical Oncology (TRACO) course will be held on Monday afternoons from September to December at the Bethesda campus, Bldg. 50 ground floor auditorium. TRACO is designed to provide an overview of general principles of cancer biology and treatment, epidemiology, mechanisms of resistance, metastasis, use of preclinical models, and identification of novel molecular targets. Participants will have an unprecedented opportunity to learn new information, glimpse into future developments of translational research in clinical oncology, meet leaders in cancer research, and interview cancer survivors. These courses are part of a curriculum for training NCI clinical and postdoctoral fellows.
For more information, visit: http://ccr.cancer.gov/careers/courses/traco
TRACO: Small molecules: Radiation oncology
-
- NCRR October 18, 2011 Staff Meeting (NIH Only)
-
- - CFC Kickoff & David Timpane (2011/10/22)
- - Category : Special
- NCRR Combined Federal Campaign Kickoff. NCRR Document Submission System
NCRR October 18, 2011 Staff Meeting (NIH Only)
-
- Regulation of the dopaminergic reward circuit and manic-like behavior by the CLOCK gene
-
- - Colleen A. McClung, Ph.D. (2011/10/22)
- - Category : BSSR Lecture Series
- Multiple studies have suggested that disruptions in circadian rhythms are central to the development of mood and addiction disorders. However, the mechanisms by which circadian genes regulate mood and reward-related circuitry remains unclear.
Our laboratory has found that mice with a mutation in the Clock gene (Clock？？？19) have a complete behavioral profile that bears a striking resemblance to human mania (including hyperactivity, lowered levels of anxiety, increased preference and self-administration of drugs, and lowered levels of depression-related behavior) which can be reversed with chronic lithium treatment. Furthermore, the Clock？？？19 mice have an increase in dopaminergic activity in the ventral tegmental area (VTA) which is also normalized with lithium treatment. We have taken multiple approaches including RNA interference and optogenetics to better understand how CLOCK regulates dopaminergic activity and how this regulation is involved in the control of behavior.
Moreover, in collaboration with Kafui Dzirasa and Miguel Nicolelis at Duke University, we found that the Clock？？？19 mice not only have increased dopaminergic activity, but also have a defect in the ability of neurons in the cortico-limbic circuit to synchronize firing while animals are exploring specific tasks. Thus the CLOCK protein is not only involved in controlling rhythms over the course of 24 hrs, but is also involved in the synchronization of activity between brain regions over short periods of time.
CLOCK functions as a transcription factor and we have identified direct target genes that control dopaminergic activity which appear to be important in the reversal of phenotypes by lithium. Taken together, these results begin to show the mechanisms by which circadian genes regulate mood and reward, and suggest novel therapeutic targets for the treatment of mania and addictive disorders.
Regulation of the dopaminergic reward circuit and manic-like behavior by the CLOCK gene
-
- John Doppman Memorial Lecture for Imaging Sciences: MR Elastography: A New Quantitative Imaging Biomarker
-
- - Richard L. Ehman, MD, Consultant, Department of Radiology, Mayo Clinic, Professor of Radiology, College of Medicine, Mayo Clinic (2011/10/22)
- - Category : Clinical Center Grand Rounds
- CC Grand Rounds Lecture Series
For more information, visit: http://www.cc.nih.gov/about/news/grcurrent.html
John Doppman Memorial Lecture for Imaging Sciences: MR Elastography: A New Quantitative Imaging Biomarker
-
- Molecular Control of Regulatory T Cell Function
-
- - Dr. Megan Leavings (2011/10/22)
- - Category : Immunology
- Immunology Interest Group Seminar
Molecular Control of Regulatory T Cell Function
-
- GMAC - 2011 NIH UPDATE (HHS Only)
-
- - Carol Wigglesworth - Grants Policy Analyst, OPERA, OER, OD; Maria Koszalka - Grants Policy Analyst, OPERA, OER, OD; Kathy Hancock - Assistant Grants Compliance Officer, OPERA, OER, OD (2011/10/21)
- - Category : GMAC (HHS Only)
- This seminar will present new and upcoming NIH policy and administrative changes that affect grantees and NIH Grants Management staff. It will also address the latest information on federal-wide initiatives, such as RPPR and the FFR, grantee requirements, electronic submission of complex mechanisms and type 3s and 7s, and changes to the FCOI regulations.
For more information, visit: http://odoerdb2.od.nih.gov/gmac/gmac/trs_main.html
GMAC - 2011 NIH UPDATE (HHS Only)
-
- BTRIS Town Hall - October 2011
-
- - James Cimino (2011/10/20)
- - Category : Special
- The Biomedical Translational Research Information System (BTRIS) is a resource available to the NIH intramural community that brings together clinical research data from the Clinical Center and other NIH Institutes and Centers. BTRIS provides clinical investigators with access to identifiable data for the subjects on their own active protocols, while providing all NIH investigators with access to de-identified data accross all protocols. Researchers are invited to see how BTRIS can help streamline the research process and assist with mandatory reporting for IRB's and Clinical Trials.gov
BTRIS Town Hall - October 2011
-
- Conflicts of Interest; Randomized Clinical Trials; Clinical Equipoise; Mock IRB (Course 3)
-
- - Steven Joffe, MD MPH; Robert Truog, MD (2011/10/16)
- - Category : Bioethics
- Ethical and Regulatory Aspects of Clinical Research
Conflicts of Interest; Randomized Clinical Trials; Clinical Equipoise; Mock IRB (Course 3)
-
- Great Teachers: Heart Matters: Old Ideas in New Times for the Patient-Doctor Relationship
-
- - Katharine Kennedy Treadway, MD, Gerald S. Foster Academy Associate Professor of Medicine, Harvard Medical School (2011/10/16)
- - Category : Clinical Center Grand Rounds
- CC Grand Rounds
For more information, visit: http://www.cc.nih.gov/about/news/grcurrent.html
Great Teachers: Heart Matters: Old Ideas in New Times for the Patient-Doctor Relationship
-
- TRACO: Breast cancer: Cancer disparities
-
- - Farah Zia: Stefan Ambs (2011/10/16)
- - Category : TRACO
- The Translational Research in Clinical Oncology (TRACO) course will be held on Monday afternoons from September to December at the Bethesda campus, Bldg. 50 ground floor auditorium. TRACO is designed to provide an overview of general principles of cancer biology and treatment, epidemiology, mechanisms of resistance, metastasis, use of preclinical models, and identification of novel molecular targets. Participants will have an unprecedented opportunity to learn new information, glimpse into future developments of translational research in clinical oncology, meet leaders in cancer research, and interview cancer survivors. These courses are part of a curriculum for training NCI clinical and postdoctoral fellows.
For more information, visit: http://ccr.cancer.gov/careers/courses/traco
TRACO: Breast cancer: Cancer disparities
-
- Kinetic Analysis of Molecular Interactions at the T Cell Surface
-
- - Dr. Cheng Zhu (2011/10/16)
- - Category : Immunology
- Immunology Interest Group Seminar
Kinetic Analysis of Molecular Interactions at the T Cell Surface
-
- ORS Directors Staff Meeting (NIH Only)
-
- - Chris Boarman, Client Services Division, OHR (2011/10/16)
- - Category : NIH Only
- After Retirement: Re-Employed Annuitant
ORS Directors Staff Meeting (NIH Only)
-
- The Emerging Network of Data for Understanding the Interactions of Genes and Drugs
-
- - Russ B. Altman, M.D., Ph.D., Stanford University (2011/10/15)
- - Category : Wednesday Afternoon Lectures
- The last two decades have provided a flood of data relevant to drug action--from both basic science and clinical sources. These data provide molecular, cellular, tissue, organism and population-level information about how drugs work to create both efficacy and adverse events. Any single data source is imperfect, but integration of these sources can yield remarkable and practical discoveries as well as opportunities for application. In this talk, I describe our recent work using informatics technologies to (1) assess the potential impact of pharmacogenomics in the era of personal genome sequencing, (2) analyze the corpus of published medical literature to extract potentially novel drug interactions along with putative mechanisms, and (3) discover a novel drug-drug interaction that may affect up to 1 million Americans. Together these efforts suggest that informatics-driven science can not only create strong hypotheses, but can provide initial validation, and suggest very focused inexpensive experimental validations.
The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
For more information, visit:
The NIH Directors Wednesday Afternoon Lecture Series
The Emerging Network of Data for Understanding the Interactions of Genes and Drugs
-
- Activation of PI3Kalpha by Physiological Effectors and by Oncogenic Mutations: Structural and Dynamic Effects
-
- - L. Mario Amzel, Ph.D., Johns Hopkins University School of Medicine (2011/10/14)
- - Category : Wednesday Afternoon Lectures
- The lipid kinase PI3Kalpha is composed of two subunits: a catalytic subunit p110 and a regulatory subunit p85. Under basal conditions p85 has an inhibitory effect on the kinase activity.
Physiological activation of PI3Ka is the result of the release of the p85 inhibition when the nSH2 binds the phosphorylated tyrosine of activated receptors or their substrates. Oncogenic mutations of PI3Ka activate the enzyme constitutively triggering downstream pathways that increase tumor aggressiveness and survival. Structural information suggests that some of these mutations also activate the enzyme by releasing p85 inhibition. Others may use different mechanisms. For example, His1047Arg, the most common oncogenic mutation, causes a conformational change that increases membrane association and greater accessibility to the substrate, an integral membrane component. Activation of the enzyme by these effects appear to be the result of a combination of conformational changes and changes in the dynamics of loop and domain-domain motions.
The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
For more information, visit:
The NIH Directors Wednesday Afternoon Lecture Series
Activation of PI3Kalpha by Physiological Effectors and by Oncogenic Mutations: Structural and Dynamic Effects
-
- Eat, Pray, Love: Affinity, Tolerance and Autoimmunity
-
- - Dr. Ed Palmer (2011/10/14)
- - Category : Immunology
- Immunology Interest Group Seminar
Eat, Pray, Love: Affinity, Tolerance and Autoimmunity
-
- Genetic Risk and Neurodegeneration
-
- - John Hardy, PhD, University College London, United Kingdom (2011/10/13)
- - Category : Neuroscience
- Neuroscience Seminar Series
Prof John Hardy is a geneticist and molecular biologist whose research interests focus on neurological disease. Dr. Hardy received his B.Sc. (Hons) degree from the University of Leeds, UK (1976) and his Ph.D. from Imperial College, London, UK where he studied dopamine and amino acid neuropharmacology. Dr. Hardy received his postdoctoral training at the MRC Neuropathogenesis Unit in Newcastle upon Tyne, UK and then further postdoctoral work at the Swedish Brain Bank in Ume？？, Sweden where he started to work on Alzheimer？？？s disease. He became Assistant Professor of Biochemistry at St. Mary？？？s Hospital, Imperial College, London in 1985 and initiated genetic studies of Alzheimer？？？s disease whilst there. He was appointed Associate Professor in 1989 and then took the Pfeiffer Endowed Chair of Alzheimer？？？s Research at the University of South Florida, in Tampa in 1992. In 1996 he moved to the Mayo Clinic in Jacksonville, Florida, as Consultant and Professor of Neuroscience. He became Chair of Neuroscience in 2000 and moved to NIA as Chief of the Laboratory of Neurogenetics in 2001. He won the MetLife, the Allied Signal and the Potamkin Prize for his work in describing the first genetic mutations, in the amyloid gene in Alzheimer？？？s disease, in 1991. He was Head of the Neurogenetics Section, National Institute of Ageing, Bethesda, USA and in 2007 took up the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology. With over 23,000 citations, Prof Hardy is the most cited Alzheimers disease researcher in the UK (5th internationally). In recognition of his exceptional contributions to science, he was elected a Fellow of the Royal Society in 2009.
Professor Hardy？？？s research interests are in the genetic analysis of disease. Historically, he has worked on the genetic analysis of Alzheimers disease and other dementias. More recently, he has worked on Parkinsons disease and other movement disorders and, most recently on motor neuron disease. His early studies were on mendelian forms of disease and these studies continue, but an increasing focus has been on the genetic analysis of complex traits related to disease. Additionally, his laboratory is increasingly interested in population genetics because the risk variants for human traits are likely to be different in different racial groups. In all cases his work moves toward developing an understanding of the underlying genetics of a disorder to enable making cellular and animal models of the disease to help, both in the understanding of disease mechanisms and to help in the search for treatments.
For more information, visit: http://neuroseries.info.nih.gov
Genetic Risk and Neurodegeneration